Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 5/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30293834 | 0.92 | NTSR2 (0.45) | NTSR2NTSR1SORT1CCNA2CDK2 | |
| SCHEMBL30296849 | 0.91 | SLC15A2 (0.38) | NTSR2NTSR1 | |
| SCHEMBL30781142 | 0.89 | SLC15A2 (0.43) | — | |
| SCHEMBL30781070 | 0.89 | SLC15A2 (0.43) | — | |
| SCHEMBL28027303 | 0.89 | SLC15A2 (0.43) | — | |
| SCHEMBL10525304 | 0.89 | SLC15A2 (0.43) | — | |
| SCHEMBL30433504 | 0.89 | NTSR2 (0.48) | NTSR2NTSR1SORT1CCNA2CDK2 | |
| SCHEMBL30536718 | 0.88 | ENPEP (0.39) | ENPEP | |
| SCHEMBL31188427 | 0.88 | SLC15A2 (0.40) | NTSR2NTSR1 | |
| SCHEMBL31453822 | 0.87 | SLC15A2 (0.47) | NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | GIPR, GLP1R, GPR119 | NTSR2 24/4885NTSR1 17/4885SORT1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.